Monitor for IND filing for EB612 in late 2026 and further clinical data for EB618. The positive preclinical data supports the platform but does not change near-term fundamentals; the stock may see modest interest from biotech investors but lacks a near-term catalyst.
Price Chart
Executive Summary
Entera Bio reported positive preclinical data at ENDO 2026 for two oral peptide programs: EB612 (hypoparathyroidism) showed sustained calcium increases across three animal models, and EB618 (obesity) demonstrated dose-proportional PK and glucose effects in non-human primates. Both programs are co-developed with OPKO Health, with an IND for EB612 expected in late 2026. The data supports Entera's N-Tab platform but is early-stage and does not alter near-term financials.
Key Facts
- EB612, a first-in-class oral long-acting PTH(1-34) analog, restored serum calcium in TPTx rat model and produced sustained calcemic effects for ~3 days in minipigs and non-human primates.
- EB618, a first-in-class oral dual GLP-1/glucagon agonist, showed dose-proportional pharmacokinetics and a robust effect on postprandial blood glucose in non-human primates.
- IND filing for EB612 is expected in late 2026; both programs are co-developed with OPKO Health (OPK) on a 50/50 basis.
- No safety concerns were identified for either candidate at doses exceeding the anticipated clinical range.
Financial Impact
No financial data provided; preclinical data only.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- Regulatory and development risks remain high for early-stage pipeline.
- Company may require additional capital to fund ongoing development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312598 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | DEF 14A | $2.77 | awaiting T+60 | — | $2.86 (+3.25%) |
Oct 6, 2026 20d ago | 8-K | $2.53 | awaiting T+60 | — | $2.86 (+13.04%) |
Aug 27, 2026 8w ago | Press Release | $3.08 | awaiting T+60 | — | $2.86 (−7.14%) |
Aug 18, 2026 9w ago | 8-K | $2.89 | awaiting T+60 | — | $2.86 (−1.04%) |
Aug 7, 2026 11w ago | Press Release | $3.04 | awaiting T+60 | — | $2.86 (−5.92%) |
Jul 29, 2026 12w ago | Press Release | $3.00 $3.02 | ▲ +0.67% | ▼ −4.06% | $2.86 (−4.67%) |
Jun 16, 2026 18w ago | Press Release | $1.18 $2.79 | ▲ +136.44% | ▲ +135.44% | $2.86 (+142.37%) |
May 28, 2026 21w ago | Press Release | $1.22 $3.23 | ▲ +164.75% | ▲ +163.02% | $2.86 (+134.43%) |
May 18, 2026 23w ago | EFFECT | $1.23 $2.80 | ▲ +127.64% | ▲ +122.79% | $2.86 (+132.52%) |
May 8, 2026 24w ago | S-3 | $1.17 $2.81 | ▲ +140.17% | ▲ +135.78% | $2.86 (+144.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers